Data Sciences – The New Analytics Paradigm

Access to data and key information for the purpose of Analytics has been a constant in the Pharmaceutical / Life Sciences / Health Care industries, and this has been true for a great deal of time. Recent industry challenges such as declining R&D productivity, increased levels of regulatory and payer scrutiny, declining sales, blockbusters going off patent, and the need to reduce healthcare costs while improving patient care etc. have only served to dramatically increase the importance of Data Sciences Analytics as a prerequisite for efficient delivery of Life Sciences and Health Care products and services.

This webinar discusses Data Sciences Analytics and the new Analytics Paradigm from an overall industry perspective along with a discussion of the MaxisIT Common Services Analytics Framework and Data Sciences Analytics Workbench functionality which MaxisIT will be implementing within its CTRenaissance® suite of clinical solutions and how the functionality is used to oversee the presentation and availability of data that will support and drive Data Sciences initiatives across the Health Care & Life Sciences industries, including Predictive Analytics.

The new Analytics & Reporting paradigm expects to be able to access additional types of data such as Claims Data, EMRs, patient behavior data, Imaging data, Cost Data etc., which have recently emerged alongside the “traditional” forms of Clinical Data produced by R&D processes. These new types of formats are available for integration and aggregation across the entire Data Sciences Analytics spectrum.

To execute this new breed of Analytics, the Role of the Data Scientist has surfaced and become more visible and important within Health Care & Life Sciences organizations. Data Scientists expand upon the more-familiar Business Analyst role by exploring and examining data located in disparate standardized and non-standardized, structured and non-structured, and internal / external data sources, with the intention of looking at data from many perspectives in order to uncover a previously hidden insight, which in turn can lead to a competitive advantage or address a pressing business problem.



“Having the highest quality clinical data and related information with efficient analytical tools available at all times is critical to managing our clinical programs and accelerating our innovation; and with MaxisIT’s Integrated Clinical Development Cloud, it was easy to achieve that across the portfolio of studies, and we were able to improve the quality of data and speed of decisions without increasing our support staff.”
Head of Clinical Projects
Multi-billion dollar pharma organization focused into rare disease
"Managing trials cost-effectively, and timely have been the biggest priorities in small biotech organizations with potential to grow; MaxisIT’s Integrated Platform just delivered that by allowing us to get faster access to data via clinical data repository, and role-based & self-service A&R platform to keep track of our clinical, operational, and administrative performance across the portfolio of oncology trials.”
Sr. Director, Project and Clinical Data Management
Oncology Biotech Company
“Implementation of MaxisIT’s clinical data repository enabled us easier, and faster access to our outsourced trials’ data in the most user-friendly manner, which improved our ability to respond to data quality issues, and conduct clinical data review in timely manner.”
Executive Director and Senior Physician Project Leader
Neurosciences Focused Business Subsidiary of one of the top 10 Pharmaceutical Companies
“Right combination of technology, process, and qualified people delivered via MaxisIT partnership enabled us to achieve above 50% reduction in protocol cycle time across the portfolio of trials, and also establish clear visibility across the trial performance.”
Head, Clinical Data Management
A Multi-billion Medical device company

This website uses cookies to help us give you the best experience when you visit. By using this website you consent to our use of these cookies. For more information on our use of cookies, please review our cookie policy.